2
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T37459 |
Lipoxin A5
|
||
Lipoxin A5 (LXA5) is produced by enzymatic transformation of EPA by leukocytes. LXA5 slowly contracts pulmonary parenchymal strips from guinea pig with similar potency to that of LXA4 and LXB4. However, LXA5 does not exert the vasodilatory effects on aortic smooth muscle exhibited by LXA4 and LXB4. | |||
T37305 |
6(S)-Lipoxin A4
6(S)-Lipoxin A4 |
||
The lipoxins are trihydroxy fatty acids containing a 7,9,11,13-conjugated tetraene. Lipoxin A4 (LXA4) was first described as a metabolite of 15-HpETE and/or 15-HETE when added in vitro to isolated human leukocytes. The material obtained in this manner consists of at least four distinct isomers: 5(S), 6(S); 5(S), 6(R); and the 11-trans and 11-cis isomers of each of these. 6(S)-LXA4 is one of the original four metabolites first identified by Serhan, Nicolaou, and Samuelsson. It was considered to b... |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T36051 |
Lipoxin A4
脂氧素 A4,LXA4 |
||
Lipoxin A4 (LXA4) is a trihydroxy fatty acid containing a conjugated tetraene, produced by the metabolism of (±)15-HETE or 15-HpETE with human leukocytes.[1] LXA4 is equipotent to leukotriene B4 in inducing superoxide generation in human neutrophils at 0.1 μM.2 LXA4 is associated with several other biological functions including leukocyte activation, chemotaxis effects, natural killer cell inhibition, and monocyte migration and adhesion.[2],[3],[4] Analytical and biological comparisons of synth... |